$VDRM$ ViaDerma = $$'s coming this year! Here's al
Post# of 103030
(Total Views: 643)
Posted On: 03/20/2017 11:10:19 AM
Re: guidelines #5878
$VDRM$ ViaDerma = $$'s coming this year! Here's all the DD you need to know.
thanks to "whatarush12"
March 8, 2017
~ Sales, labeling & marketing being launched!! Industry expert hired!! ~
http://www.marketwired.com/press-release/viad...201662.htm
~Ivan Klarich Reviews~
https://www.linkedin.com/in/ivanklarich/
Aidan Roark Makepeace
Founder/CEO at WRKPRTY
Aidan Roark worked with Ivan in different groups
I have had the privilege of working with and for Ivan on several software development and business strategy projects ranging from the start-up to the enterprise level and can say, without reservation, Ivan is amazing to work with. Ivan is a thoughtful and inspiring leader and team-builder, and an energetic, diligent, and reliable visionary in strategic planning and operations/executive management. I welcome every opportunity to work with Ivan and can wholeheartedly recommend his services, as well as those of his extensive team of associates.
Mireille Buiel
HR Lead at FindHotel
Mireille worked with Ivan but at different companies
I have worked together with Ivan as consultants at a California based FMCG manufacturing company. I got to know him as a value-based strategic thinker that keeps his eye on the long-term goal. He is able to bring teams and entrepreneurs quickly to the ‘pain points’ and find new practical solutions for their business (model) issues. I would definitely recommend him for complex organizational and commercial challenges.
John Fanaris
Co-Owner/GM/Sommelier at Rustic Kitchen
John worked with Ivan but at different companies
Preparing for growth and putting the right pieces together are crucial to success and Ivan brings the tools needed to the table. He has a non-confrontational demeanor in his analysis of your internal methodology with the uncanny knack of straight forward communication and a tell-it-like-it-is constructive advice. He is an expert at analyzing company operations and culture to develop a comprehensive strategy to reach your goals. If you are looking to take your company to the next level, Ivan is your man.
Jackie Lapin / Authors, Speakers, Get Leads, Get Booked
?? AUTHORS & SPEAKERS, GET LEADS, GET BOOKED–Book Your Own Speaking Engagements at Transformational Venues & Events
Jackie Lapin / worked with Ivan but at different companies
Ivan is one of the most brilliant forward-thinking business visionaries I've ever encountered. That skill is anchored by real world practical strategic analytics and implementation that ensures success. I want him on my team whenever I'm launching something new, improve what's already working or need to fix something that's not!
February 15, 2017
~ Additional patents are being filed in the MMJ space! ~
http://www.marketwired.com/press-release/viad...196107.htm
http://www.thedailychronic.net/2017/68842/cli...diabetics/
http://www.thedailychronic.net/2017/69698/stu...f-opioids/
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 21-23, 2017 ~
http://www.marketwired.com/press-release/dr-c...194656.htm
February 3, 2017
~ MASSIVE sales coming.. 500,000 units x $125 = $62,500,000 in 2017~
http://www.marketwired.com/press-release/viad...193323.htm
January 11, 2017
~Filed a patent application with the USPTO for its proprietary innovative transdermal delivery system~
http://www.marketwired.com/press-release/viad...187878.htm
November 30, 2016
"Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas,
http://www.marketwired.com/press-release/viad...179850.htm
November 14, 2016
Filed Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases
http://www.marketwired.com/press-release/viad...175498.htm
Current Market Cap ~ $9.5mill, March 10, 2017~
Share Structure
Authorized Shares 400,000,000 a/o Mar 07, 2017
Outstanding Shares 321,232,603 a/o Mar 07, 2017
-Restricted 57,975,478 a/o Mar 07, 2017
-Unrestricted 263,257,125 a/o Mar 07, 2017
Held at DTC 246,331,609 a/o Mar 07, 2017
Float 222,337,825 a/o Jan 25, 2017
2dollarbill ~ REPOST
just doing my part here...
Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transform oral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.
Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with a diffusion constant 10,000x higher. Strong Advanced Biological Coverage (ABC) which has higher concentrations, faster penetration and is more effective than conventional antibiotics. ABC produces desirable results in ~24 hours or less compared to 5-7 days. It kills all harmful gram-positive and gram-negative bacteria that have been available for testing.
1- back in 2.25.2014 philips manufactured there last fda approval of tetrastem, its a 3 year shelf life as im able to see
2 - in 5.28.2014 VDRM started to manufacture there first fda approval of tetrastem, same 3 year shelf life
3 - now heres where it make huge sense in 3.2014 VDRM gets the rights to manufacture tetrastem from phlips....1 month after they start there first manufacture of tetrastem
4 - the 3 - 6 - 9 month studies kick in in a huge way, and now VDRM as of 1.2017 manufactures 500,000 bottles for sale,
...basically they took what worked expanded on it and said this is huger than we thought
5 - 12.2016 VDRM files for uopdated Viabecline patent - which is purely application - so that means anyone, anywhere, anytime they use tetrastem - pure play on licensing application
6 - back in 2015 rumors started that both PFE and MRK and Endo pharma were looking at VDRM
7 - 2.2017 Dr Otiko to write a paper on diabetic ulcers showing massive results - which means all roads to viabecline
articles of interest ( get them off the web )
1 - from a 2.2011 study reposted in 1.2017 paraplegic uses tetrastem with stem cells and walks again ( philips put the article out )
2 - 3.2015 onychmycosis article
3 - 11.2016 viabecline article
4 - 12.2016 diabetic ulcers study vdrm issued
5 - 12.2016 viabecline patent applied for
6 - 1.2017 vdrm 500,000 bottles manufactured for 2017 grossing 62-65M in sales
viabecline is a delivery of tetrastem - which can take any oral as well and apply to ointment application
PFE is all about viagra, now imagine a lotion for f on f , not just a pill, and youve opened a huge market in the world away of same sex...mrk is all about diabetes and with application wise they want in too, add in JNJ which bandaids work and graduate to a 1000% increase in healing and they want in too...
VDRM product is 85% cheaper and works better - Viabecline is what the entire game is all about here - application technology
PFE Viagra is a category killer but it is a pill - and a pill is a introduction internally to the blood stream which out of fear a great portion of the population will just not take, now factor in a female Viagra alternative that is topical and replace the male Viagra with the same topical and its obvious that PFE will be forced to enter some sort of licensing agreement to hold onto there market share and as well look to capitalize on the female market as well ( m on f , and f on f ) there are those that will only use topical not internal
MRK, LLY and MNKD are the diabetic market and its huge - toenail fungal market - now add on a turnaround solution they have been needing for years, to treat at home foot infections ( home care largest market globally ) and that market alone is extraordinary with multiple companies all vying to be the dominant player and VDRM having the solution to license
JNJ marketplace is wounds - the band , now graduate it to the ability to speed the process up say 10 fold to heal any scrapes scratched wounds and to hold there market-share JNJ will be forced to enter some sort of licensing deal just to hold the line or risk crippling there empire quite easily
MRK and JNJ baldness market is in a level all itself, as its a do it yourself world we live in - add a just for men/ ladies crowd solution to expand into the baldness market and make that a CVS Walgreen's etc play for direct access more licensing
without even touching on the other markets there is exceptional growth here
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
~Info on Dr. Chris Otiko, CEO of ViaDerma~
Radio interview from December 9, 2016. https://upticknewswire.com/viaderma-ceo-dr-ch...ic-wounds/
https://www.linkedin.com/in/chris-ayo-otiko-80284b5/
https://www.linkedin.com/pulse/healing-diabet...otic-otiko
https://www.barbadostoday.bb/2014/07/05/mirac...diabetics/
http://www.neurogenx.com/testimonial/christop...-director/
https://www.ratemds.com/doctor-ratings/233443...da-CA.html
~Patent/Licensing/Manufacturing Info~
https://www.drugs.com/otc/129916/tetrastem.html
(licensed as Diabecline and Viabecline). Regardless of who owns or has the rights to the patent, ViaDerma has licensing rights, and has filed a new patent pending application for the transdermal system as per January 11, 2017 PR
AND TODAY, PATENT NUMBERS ASSIGNED BY USPTO:
"LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
GLTA
LONG $VDRM
thanks to "whatarush12"
March 8, 2017
~ Sales, labeling & marketing being launched!! Industry expert hired!! ~
http://www.marketwired.com/press-release/viad...201662.htm
~Ivan Klarich Reviews~
https://www.linkedin.com/in/ivanklarich/
Aidan Roark Makepeace
Founder/CEO at WRKPRTY
Aidan Roark worked with Ivan in different groups
I have had the privilege of working with and for Ivan on several software development and business strategy projects ranging from the start-up to the enterprise level and can say, without reservation, Ivan is amazing to work with. Ivan is a thoughtful and inspiring leader and team-builder, and an energetic, diligent, and reliable visionary in strategic planning and operations/executive management. I welcome every opportunity to work with Ivan and can wholeheartedly recommend his services, as well as those of his extensive team of associates.
Mireille Buiel
HR Lead at FindHotel
Mireille worked with Ivan but at different companies
I have worked together with Ivan as consultants at a California based FMCG manufacturing company. I got to know him as a value-based strategic thinker that keeps his eye on the long-term goal. He is able to bring teams and entrepreneurs quickly to the ‘pain points’ and find new practical solutions for their business (model) issues. I would definitely recommend him for complex organizational and commercial challenges.
John Fanaris
Co-Owner/GM/Sommelier at Rustic Kitchen
John worked with Ivan but at different companies
Preparing for growth and putting the right pieces together are crucial to success and Ivan brings the tools needed to the table. He has a non-confrontational demeanor in his analysis of your internal methodology with the uncanny knack of straight forward communication and a tell-it-like-it-is constructive advice. He is an expert at analyzing company operations and culture to develop a comprehensive strategy to reach your goals. If you are looking to take your company to the next level, Ivan is your man.
Jackie Lapin / Authors, Speakers, Get Leads, Get Booked
?? AUTHORS & SPEAKERS, GET LEADS, GET BOOKED–Book Your Own Speaking Engagements at Transformational Venues & Events
Jackie Lapin / worked with Ivan but at different companies
Ivan is one of the most brilliant forward-thinking business visionaries I've ever encountered. That skill is anchored by real world practical strategic analytics and implementation that ensures success. I want him on my team whenever I'm launching something new, improve what's already working or need to fix something that's not!
February 15, 2017
~ Additional patents are being filed in the MMJ space! ~
http://www.marketwired.com/press-release/viad...196107.htm
http://www.thedailychronic.net/2017/68842/cli...diabetics/
http://www.thedailychronic.net/2017/69698/stu...f-opioids/
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 21-23, 2017 ~
http://www.marketwired.com/press-release/dr-c...194656.htm
February 3, 2017
~ MASSIVE sales coming.. 500,000 units x $125 = $62,500,000 in 2017~
http://www.marketwired.com/press-release/viad...193323.htm
January 11, 2017
~Filed a patent application with the USPTO for its proprietary innovative transdermal delivery system~
http://www.marketwired.com/press-release/viad...187878.htm
November 30, 2016
"Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas,
http://www.marketwired.com/press-release/viad...179850.htm
November 14, 2016
Filed Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases
http://www.marketwired.com/press-release/viad...175498.htm
Current Market Cap ~ $9.5mill, March 10, 2017~
Share Structure
Authorized Shares 400,000,000 a/o Mar 07, 2017
Outstanding Shares 321,232,603 a/o Mar 07, 2017
-Restricted 57,975,478 a/o Mar 07, 2017
-Unrestricted 263,257,125 a/o Mar 07, 2017
Held at DTC 246,331,609 a/o Mar 07, 2017
Float 222,337,825 a/o Jan 25, 2017
2dollarbill ~ REPOST
just doing my part here...
Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transform oral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.
Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with a diffusion constant 10,000x higher. Strong Advanced Biological Coverage (ABC) which has higher concentrations, faster penetration and is more effective than conventional antibiotics. ABC produces desirable results in ~24 hours or less compared to 5-7 days. It kills all harmful gram-positive and gram-negative bacteria that have been available for testing.
1- back in 2.25.2014 philips manufactured there last fda approval of tetrastem, its a 3 year shelf life as im able to see
2 - in 5.28.2014 VDRM started to manufacture there first fda approval of tetrastem, same 3 year shelf life
3 - now heres where it make huge sense in 3.2014 VDRM gets the rights to manufacture tetrastem from phlips....1 month after they start there first manufacture of tetrastem
4 - the 3 - 6 - 9 month studies kick in in a huge way, and now VDRM as of 1.2017 manufactures 500,000 bottles for sale,
...basically they took what worked expanded on it and said this is huger than we thought
5 - 12.2016 VDRM files for uopdated Viabecline patent - which is purely application - so that means anyone, anywhere, anytime they use tetrastem - pure play on licensing application
6 - back in 2015 rumors started that both PFE and MRK and Endo pharma were looking at VDRM
7 - 2.2017 Dr Otiko to write a paper on diabetic ulcers showing massive results - which means all roads to viabecline
articles of interest ( get them off the web )
1 - from a 2.2011 study reposted in 1.2017 paraplegic uses tetrastem with stem cells and walks again ( philips put the article out )
2 - 3.2015 onychmycosis article
3 - 11.2016 viabecline article
4 - 12.2016 diabetic ulcers study vdrm issued
5 - 12.2016 viabecline patent applied for
6 - 1.2017 vdrm 500,000 bottles manufactured for 2017 grossing 62-65M in sales
viabecline is a delivery of tetrastem - which can take any oral as well and apply to ointment application
PFE is all about viagra, now imagine a lotion for f on f , not just a pill, and youve opened a huge market in the world away of same sex...mrk is all about diabetes and with application wise they want in too, add in JNJ which bandaids work and graduate to a 1000% increase in healing and they want in too...
VDRM product is 85% cheaper and works better - Viabecline is what the entire game is all about here - application technology
PFE Viagra is a category killer but it is a pill - and a pill is a introduction internally to the blood stream which out of fear a great portion of the population will just not take, now factor in a female Viagra alternative that is topical and replace the male Viagra with the same topical and its obvious that PFE will be forced to enter some sort of licensing agreement to hold onto there market share and as well look to capitalize on the female market as well ( m on f , and f on f ) there are those that will only use topical not internal
MRK, LLY and MNKD are the diabetic market and its huge - toenail fungal market - now add on a turnaround solution they have been needing for years, to treat at home foot infections ( home care largest market globally ) and that market alone is extraordinary with multiple companies all vying to be the dominant player and VDRM having the solution to license
JNJ marketplace is wounds - the band , now graduate it to the ability to speed the process up say 10 fold to heal any scrapes scratched wounds and to hold there market-share JNJ will be forced to enter some sort of licensing deal just to hold the line or risk crippling there empire quite easily
MRK and JNJ baldness market is in a level all itself, as its a do it yourself world we live in - add a just for men/ ladies crowd solution to expand into the baldness market and make that a CVS Walgreen's etc play for direct access more licensing
without even touching on the other markets there is exceptional growth here
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
~Info on Dr. Chris Otiko, CEO of ViaDerma~
Radio interview from December 9, 2016. https://upticknewswire.com/viaderma-ceo-dr-ch...ic-wounds/
https://www.linkedin.com/in/chris-ayo-otiko-80284b5/
https://www.linkedin.com/pulse/healing-diabet...otic-otiko
https://www.barbadostoday.bb/2014/07/05/mirac...diabetics/
http://www.neurogenx.com/testimonial/christop...-director/
https://www.ratemds.com/doctor-ratings/233443...da-CA.html
~Patent/Licensing/Manufacturing Info~
https://www.drugs.com/otc/129916/tetrastem.html
(licensed as Diabecline and Viabecline). Regardless of who owns or has the rights to the patent, ViaDerma has licensing rights, and has filed a new patent pending application for the transdermal system as per January 11, 2017 PR
AND TODAY, PATENT NUMBERS ASSIGNED BY USPTO:
"LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
GLTA
LONG $VDRM
(0)
(0)Scroll down for more posts ▼